Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w
Crossref DOI link: https://doi.org/10.1007/s12325-019-01168-1
Published Online: 2019-12-14
Published Print: 2020-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Song, Jinlin
Gao, Wei
Xie, Jipan
Tiwana, Simran
Funding for this research was provided by:
Amgen
Text and Data Mining valid from 2019-12-14
Version of Record valid from 2019-12-14
Article History
Received: 25 November 2019
First Online: 14 December 2019